Obiettivo
- Development of microspheres for the removal of endotoxins, cytokines TNFalpha and IL-1beta, exotoxin SEB, bilirubin and toxins of liver failure
- Development of biodegradable endotoxin binding microspheres as a tool of higher safety of MDS.
- Development of MDS-device including the optimization of the plasma filter and the establishment of an intelligent software and hardware to accomplish high safety standards and facilitated handling
- In vivo testing and clinical testing of MDS in specific animal models (endotoxin shock and liver failure) and patients suffering from MOF, respectively
Multi organ failure (MOF), very common in septic shock patients of any age, is a multifactorial disease involving nearly all organs and systems of the human being. Its average mortality is in a range of 40-50%, and prognosis has not significantly improved during the last 10 years. The course of MOF is characterized by complex structure, initiated by endotoxins, followed by a cascade-like activation of different cells and systems. The main objective of this proposal is to establish a therapeutically system which is able to influence the multi-factorial pathophysiology at 3 different levels. The first level concentrates on the removal of free soluble endotoxins and exotoxins from blood. The second level is concerned with the removal of the principal cytokines, TNF-a and IL-1 +, by specific adsorbents. Finally, the third level includes the therapy of acute liver failure, including hepato-renal syndrome. This three step concept is based on a very recently introduced blood purification technology: the WMicrospheres based Detoxification System"(MDS). MDS is a newly developed adsorptive technology, based on a simultaneous adsorption/filtration technique, which employs microspheres in the size of 2-4,um. A suspension containing the microspheres is recirculated very rapidly and is mixed into filtrated plasma from the patient, thereby removing undesirable substances. Due to the very efficient structure of the adsorbent particles, only relatively small amounts are required, which can be applied in combinationor in sequence.
The microspheres developed are selective (use of immobilized functional groups) or specific (use of immobilized antibodies) for the removal of endotoxins, exotoxins, TNF-, IL-1 +, live rrelated substances such asphenols, thiols, aromatic amino acids or other lipophilic substances as well as protein bound substances such as bilirubin. The MDS will be designed for continuous use in intensive care units. A plasmafilter specifically designed to offer optimal conditions for continuous filtration is integrated in the blood circuit. Special sensors, the possibleuse of biodegradable microspheres, the application of magnetic microspheres, which can be replaced without any loss of plasma, and the integration of a centrifugal pump to achieve fast recirculation of the microsphere suspension make MDS a high-tech device in blood purification therapy. The system can be combined with continuous filtration in the secondary circuit, removing uraemic substances including other water-soluble toxins in the middle molecular range. In future, additional possibilities such as the use of hepatocytes or other cells could transform MDS into a bioartificial system. The project is an interdisciplinary one, which includes the development of technically very advanced materials and equipment, which will be tested in vivo and clinically during the duration of the project. It also opens new ways of specific blood purification therapy in other fields of medicine such as metabolic, autoimmune or cancer diseases. These ambitious goals can only be achieved by an international cooperation at European level. The project proposal is designed for a fast transfer of the new technology in industrial production, involving clinical testing but also partners with industrial experience. In conclusion, the project offers European industry new perspectives to compete against industries from the USA and Japan by establishing a complete new technology for blood purification therapy.
Campo scientifico (EuroSciVoc)
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.
- scienze agricole biotecnologia agricola
- scienze mediche e della salute medicina di base fisiologia fisiopatologia
- scienze mediche e della salute medicina clinica rianimazione
- scienze mediche e della salute medicina clinica oncologia
- scienze naturali scienze chimiche chimica organica ammine
È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione
Programma(i)
Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.
Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.
Argomento(i)
Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.
Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.
Invito a presentare proposte
Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.
Dati non disponibili
Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.
Meccanismo di finanziamento
Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.
Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.
Coordinatore
3500 Krems
Austria
I costi totali sostenuti dall’organizzazione per partecipare al progetto, compresi i costi diretti e indiretti. Questo importo è un sottoinsieme del bilancio complessivo del progetto.